Neurogene (NGNE) Operating Expenses (2013 - 2026)
Neurogene's (NGNE) quarterly Operating Expenses came in at $33.3 million in Q1 2026, up 28.67% YoY from $25.9 million in Q1 2025, and up 21.14% on a QoQ basis from $27.5 million in Q4 2025.
Neurogene (NGNE) Operating Expenses (2013 - 2026) Analysis & Trends
Neurogene (NGNE) has 14 years of Operating Expenses data on file, last reported at $33.3 million in Q1 2026.
- Quarterly Operating Expenses rose 28.67% year-over-year to $33.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $110.8 million (up 22.15% YoY) and the FY2025 annual result came in at $103.3 million, up 23.7% from the prior year.
- Operating Expenses grew to $33.3 million in Q1 2026, from $27.5 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $33.3 million in Q1 2026 to a low of $11.7 million in Q4 2022.
- A 5-year average of $19.5 million and a median of $18.8 million in 2024 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2022 — Operating Expenses retreated 23.09% — and 2024, when it jumped 67.19%.
- Tracing NGNE's Operating Expenses over 5 years: stood at $11.7 million in 2022, then grew by 26.24% to $14.7 million in 2023, then soared by 46.01% to $21.5 million in 2024, then climbed by 27.97% to $27.5 million in 2025, then grew by 21.14% to $33.3 million in 2026.
- The last three Operating Expenses figures came in at $33.3 million (Q1 2026), $27.5 million (Q4 2025), and $23.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Neurogene | 815.03 Mn | 815.03 Mn | - | 36.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.67 Mn |
| Mar 31, 2026 | 33.35 Mn |
| Dec 31, 2025 | 27.53 Mn |
| Sep 30, 2025 | 23.80 Mn |
| Jun 30, 2025 | 26.08 Mn |
| Mar 31, 2025 | 25.92 Mn |
| Dec 31, 2024 | 21.51 Mn |
| Sep 30, 2024 | 22.18 Mn |
| Jun 30, 2024 | 21.06 Mn |
| Mar 31, 2024 | 18.78 Mn |
| Dec 31, 2023 | 14.73 Mn |
| Sep 30, 2023 | 15.22 Mn |
| Jun 30, 2023 | 12.60 Mn |
| Mar 31, 2023 | 13.04 Mn |
| Dec 31, 2022 | 11.67 Mn |
| Sep 30, 2022 | 13.61 Mn |
| Jun 30, 2022 | 15.87 Mn |
| Mar 31, 2022 | 15.37 Mn |
| Dec 31, 2021 | 15.17 Mn |
| Sep 30, 2021 | 15.45 Mn |